Antheia: $56 Million Series C Raised For Advancing Global Commercialization Strategy
By Amit Chowdhry ● Jun 7, 2025
Antheia, a pharmaceutical ingredient manufacturer transforming essential medicine supply chains, announced it has raised $56 million in Series C financing. The Series C funding round was led by Global Health Investment Corporation (GHIC), a U.S.-based investment firm with an established history of supporting innovation in global health and health security and EDBI, operating under SG Growth Capital - the investment platform of the Singapore Economic Development Board (EDB) and Enterprise Singapore. And new investors in this round include ATHOS KG and Federov, with participation from existing investors such as Viking Global Investors, Sherpalo Ventures, S-Cubed Capital, In-Q-Tel (IQT), and Civilization Ventures.